Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE by Crauwels, HM et al.
POSTER PRESENTATION Open Access
Effect of intrinsic and extrinsic factors on the
pharmacokinetics of TMC278 in antiretroviral-
naïve, HIV-1-infected patients in ECHO and
THRIVE
HM Crauwels
1*, E van Schaick
2, RPG van Heeswijk
1, S Vanveggel
1, K Boven
3, P Vis
1
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
Purpose of the study
The current analysis examined the pharmacokinetics of
the next-generation investigational NNRTI, TMC278, in
the pooled double-blind Phase III trials ECHO
(NCT00540449) and THRIVE (NCT00543725) in ARV-
naïve, HIV-1-infected adults [1] and explored the influ-
ence of intrinsic and extrinsic factors on the pharmaco-
kinetic parameters.
Methods
A total of 1368 patients (24% female) were randomised
(1:1) to either TMC278 25 mg q.d. or EFV 600 mg q.d.,
in combination with TDF/FTC (ECHO) or a choice of
either TDF/FTC or AZT/3TC or ABC/3TC (THRIVE).
The pharmacokinetics of TMC278 were best described
by a two-compartment disposition model in which
absorption was characterised by a lag time followed by a
sequential zero- and first-order process. Individual values
for TMC278 trough plasma concentrations (Ctrough)a n d
area under the plasma concentration-time profile over
the dosing interval (AUC24h) were estimated from sparse
pharmacokinetic sampling in 679 patients in the
TMC278 treatment group (8 samples/48 weeks/patient)
using the population pharmacokinetic model. In addition,
the potential relationship between selected covariates and
the TMC278 apparent oral clearance was evaluated.
Results
T h e r ew e r en od i f f e r e n c e si nt h ep h a r m a c o k i n e t i c so f
TMC278 between the two trials. The mean (SD)
TMC278 Ctrough and AUC24h for the pooled trials were
80.0 (36.5) ng/mL and 2397 (1032) ng*h/mL, respec-
tively. The apparent oral clearance of TMC278 was esti-
mated to be 11.8 L/h (inter-individual variability 39%)
and the apparent volume of the central compartment
was estimated to be 152 L (inter-individual variability
117%). The exposure to TMC278 was not influenced by
N(t)RTI background medication, age, bodyweight, BMI,
estimated glomerular filtration rate and hepatitis B and/
or C co-infection status. Gender and race had a statisti-
cally significant effect on the TMC278 apparent oral
clearance, resulting in a slightly lower apparent oral
clearance (and thus higher AUC24h) in females (13.6%
lower clearance), and in Asian patients (17.2% lower
clearance). These small effects had little impact on the
overall inter-individual variability in apparent oral clear-
ance and are considered not to be of clinical relevance.
Conclusions
A population pharmacokinetic model was developed,
describing the pharmacokinetics of TMC278 in ARV-
naïve, HIV-1-infected adults receiving TMC278 25 mg
q.d. No covariates with a clinically relevant effect on
exposure to TMC278 were identified.
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